Breast diseases

PubMed Free Full Text

Breast cancer treatment: tyrosine kinase inhibitors

Brazil

• Breast Cancer : Targets and Therapy
  • Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective [2012]

China

• OncoTargets and Therapy
  • Lapatinib for the treatment of breast cancer in the People’s Republic of China [2014]

• PLoS ONE
  • Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review [2023]

Europe

• European Medicines Agency
  • Tyverb
  • Tukysa
  • Nerlynx

Europe, United States

• Clinical Breast Cancer
  • Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer [2021]

France

• Haute Autorité de Santé
  • NERLYNX [2020]

International

• Cancer Medicine
  • Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis [2023]

• ESMO Open
  • Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis [2022]

• Experimental and Therapeutic Medicine
  • Tyrosine kinase inhibitors in breast cancer (Review) [2022]

• Frontiers in Pharmacology
  • Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer [2022]

• Molecular Medicine
  • Neratinib for HER2-positive breast cancer with an overlooked option [2020]

Italy, Spain

• Breast
  • "Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" [2024]

United Kingdom

• National Institute for Health and Care Excellence
  • Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab [2019]

United States

• Food and Drug Administration
  • FDA approves neratinib for metastatic HER2-positive breast cancer [2020]

• Journal of the Advanced Practitioner in Oncology
  • Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer [2018]

• npj Breast Cancer
  • HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now [2021]

• Signal Transduction and Targeted Therapy
  • Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management [2023]

{Related topics}

• Topic
  • Breast cancer treatment